title: Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model.
abstract: BACKGROUND
  The optimal duration of oral anticoagulant therapy for patients with a first episode of deep vein thrombosis (DVT) is still a matter of debate. However, according to the ACCP consensus strategy a limited stratification in treatment duration is advocated, i.e. 3 months for patients with a transient risk factor and 1 year or longer for patients with recurrent disease or a consistent risk factor such as thrombophilia or cancer. This consensus strategy is founded on the mean optimal duration of therapy obtained in large cohorts of patients and is mainly based on the risk of recurrent venous thromboembolism (VTE), with only minimal consideration for the patient's bleeding risk.
  
  
  OBJECTIVE
  The aim of this study is to optimize the anticoagulant treatment strategy with vitamin K antagonists for the individual patient with DVT.
  
  
  METHODS
  Based on an extensive literature study, a mathematical model was constructed to balance the risk of recurrent VTE against the risk of major hemorrhagic complications. The following parameters are incorporated in the model: baseline estimates and risk factors for recurrent VTE and bleeding, clinical course of DVT, and efficacy of treatment with vitamin K antagonists. With the use of these parameters, the risk for a recurrent VTE and a bleeding episode can be calculated for the individual patient. The optimal duration of anticoagulant therapy can be defined as the timepoint at which the benefit of treatment (prevention of VTE) is counterbalanced by its risk (bleeding).
  
  
  CONCLUSIONS
  How long a patient should receive anticoagulant treatment is a matter of balancing the benefits and risks of treatment. The model shows that the optimal treatment duration varies greatly from patient to patient according to the patient's unique bleeding and recurrence risk.
authors.affiliation: Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands. r.vink@amc.uva.nl
authors.forename: R
authors.initials: R
authors.lastname: Vink
authors.forename: R A
authors.initials: RA
authors.lastname: Kraaijenhagen
authors.forename: M
authors.initials: M
authors.lastname: Levi
authors.forename: H R
authors.initials: HR
authors.lastname: Büller
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004360:Drug Therapy, Computer-Assisted; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D012008:Recurrence; D012306:Risk; D013927:Thrombosis / Q000188:drug therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D014812:Vitamin K